The Pharmacology of New Antiepileptic Drugs: Does a Novel Mechanism of Action Really Matter?

By Perucca Emilio  

CNS Drugs, Vol. 25, Iss. 11, 2011-11 ,pp. : 907-912

Adis International

Access to resources Recommend Favorite

Productivity Costs in Health-State Valuations: Does Explicit Instruction Matter?

By Krol Marieke   Brouwer Werner   Sendi Pedram  

PharmacoEconomics, Vol. 24, Iss. 4, 2006-01 ,pp. : 401-414

Adis International

Access to resources Recommend Favorite

Clinical Pharmacokinetics in the 21st Century: Does the Evidence Support Definitive Outcomes?

By Ensom H.  

Clinical Pharmacokinetics, Vol. 34, Iss. 4, 1998-04 ,pp. : 265-279

Adis International

Access to resources Recommend Favorite

Does Olanzapine Warrant Clinical Pharmacokinetic Monitoring in Schizophrenia?

By Schwenger Erin   Dumontet Jane   Ensom Mary H.H.  

Clinical Pharmacokinetics, Vol. 50, Iss. 7, 2011-07 ,pp. : 415-428

Adis International

Access to resources Recommend Favorite

Do Productivity Costs Matter?: The Impact of Including Productivity Costs on the Incremental Costs of Interventions Targeted at Depressive Disorders

By Krol Marieke   Papenburg Jocé   Koopmanschap Marc   Brouwer Werner  

PharmacoEconomics, Vol. 29, Iss. 7, 2011-07 ,pp. : 601-619

Adis International

Access to resources Recommend Favorite